Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of BT5528 Alone and With Nivolumab in Advanced Solid Tumors
NCT04180371Phase 2Active, not recruiting
- Sponsor
- Bicycle Therapeutics
- Start
- Nov 2019
- Primary completion
- Dec 2026
- Modality
- Cyclic Peptides, Peptide-Drug Conjugates
- Countries
- 5
01
Overview
Phase 2, open-label trial of nuzefatide pevedotin in solid tumor, urothelial carcinoma (UC), ovarian cancer and 4 more (3 arms), sponsored by Bicycle Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events, Maximum Tolerated Dose and 7 more. Started Nov 2019; status: active, not recruiting.
02
Drugs
nuzefatide pevedotin
03
Conditions
solid tumorurothelial carcinoma (UC)ovarian cancernon-small cell lung cancer (NSCLC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT04180371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04180371.